Abstract
The development of novel treatment strategies for therapy of angiogenesis-dependent diseases requires identification of specific tumor endothelial cell markers to which therapeutic agents can be targeted. This can be achieved by random or targeted approaches. Random approaches are based on genomic screening to identify differences between normal and activated endothelium. Targeted approaches utilize known angiogenesis inhibitors to find their molecular targets. Both approaches may lead to the development of angiostatic therapies that are directly targeted towards activated endothelial cells. This review summarizes the recent developments in both approaches.
Keywords: HUVEC proliferation, angiogenesis, NGR binding motifs, endothelial cell based targets, Tumor
Current Pharmaceutical Design
Title: Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango
Volume: 13 Issue: 35
Author(s): Victor L.J.L. Thijssen, Judy R. van Beijnum, Kevin H. Mayo and Arjan W. Griffioen
Affiliation:
Keywords: HUVEC proliferation, angiogenesis, NGR binding motifs, endothelial cell based targets, Tumor
Abstract: The development of novel treatment strategies for therapy of angiogenesis-dependent diseases requires identification of specific tumor endothelial cell markers to which therapeutic agents can be targeted. This can be achieved by random or targeted approaches. Random approaches are based on genomic screening to identify differences between normal and activated endothelium. Targeted approaches utilize known angiogenesis inhibitors to find their molecular targets. Both approaches may lead to the development of angiostatic therapies that are directly targeted towards activated endothelial cells. This review summarizes the recent developments in both approaches.
Export Options
About this article
Cite this article as:
Thijssen L.J.L. Victor, van Beijnum R. Judy, Mayo H. Kevin and Griffioen W. Arjan, Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango, Current Pharmaceutical Design 2007; 13 (35) . https://dx.doi.org/10.2174/138161207782794121
DOI https://dx.doi.org/10.2174/138161207782794121 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Degradation Pathways after Brain Ischemia
Current Drug Targets Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery PET Tracers Based on 86Y
Current Radiopharmaceuticals Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued) Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism The Current Status of Novel PET Radio-Pharmaceuticals in Radiotherapy Treatment Planning of Glioma
Current Pharmaceutical Biotechnology Beneficial Effects of Herbs, Spices and Medicinal Plants on the Metabolic Syndrome, Brain and Cognitive Function
Central Nervous System Agents in Medicinal Chemistry Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors
Current Pharmaceutical Design A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells
Anti-Cancer Agents in Medicinal Chemistry Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines
Current Pharmaceutical Design Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Contrast Functions of αA- and αB-Crystallins in Cancer Development
Current Molecular Medicine Recent Progress in Discovery and Development of Antimitotic Agents
Anti-Cancer Agents in Medicinal Chemistry Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Effect of Prostaglandins on the Regulation of Tumor Growth
Current Medicinal Chemistry - Anti-Cancer Agents